Preclinical immunogenicity of the LP.8.1-adapted BNT162b2 COVID-19 vaccine
Chaitanya KurhadeiD, Wei J. CheniD, Weiqiang LiiD, Kristin R. TompkinsiD, Lyndsey T. MartineziD, Swati Rajput, Emily Babiarz, Aaron Yam, Shin-Ae Lee, Shikha ShrivastavaiD, Sarah O’LearyiD, Subrata Saha, Hui Qing YaoiD, Hao LiiD, Todd S. CoffeyiD, Carla Iris Cadima Couto, Alexander MuikiD, Raquel Munoz Moreno, Wesley Swanson, Pilar Mendoza, Uğur ŞahiniD, Annaliesa S. AndersoniD, Kena A. SwansoniD, Pirada Suphaphiphat AlleniD, Kayvon ModjarradiD
Abstract
SARS-CoV-2 evolution toward antigenically distinct lineages drives escape from host immunity. JN.1 lineage derivatives have recently dominated the global epidemiologic landscape. In preclinical models, an LP.8.1-adapted BNT162b2 vaccine elicited higher serum neutralizing antibody responses against contemporary, circulating JN.1 sublineages, including the currently dominant XFG, as compared to JN.1-, KP.2- and XEC-adapted vaccines. These findings supported the selection of an LP.8.1-adapted vaccine for the composition of the 2025-26 COVID-19 vaccine formula.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- FWCI
- 4.95
- Field percentile
- top 11%
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Immunologic and Biophysical Features of the BNT162b2 JN.1- and KP.2-Adapted COVID-19 Vaccines
Wei J. Chen, Kristin R. Tompkins, … Kayvon Modjarrad·Nature CommunicationsPeer-reviewed·Dec 5, 2025
- Humoral immunity induced by LP.8.1 monovalent vaccines against a broad range of SARS-CoV-2 variants including XEC, NB.1.8.1, XFG, and BA.3.2
Yu Kaku, Mizuka Fujiwara, … Kei Sato·bioRxiv·Nov 18, 2025
- mRNA-1273.251 and mRNA-1283.251 vaccines expressing SARS-CoV-2 variant LP.8.1 antigens broadly neutralize contemporary JN.1-lineage viruses
Arshan Nasir, Diana Wing Lee, … Alec W. Freyn·bioRxiv·Sep 16, 2025
- mRNA-1273 vaccines adapted to JN.1 or KP.2 elicit cross-neutralizing responses against the JN.1 sublineages of SARS-CoV-2 in mice
Diana Wing Lee, Arshan Nasir, … Yadunanda Budigi·VaccinePeer-reviewed·Mar 7, 2025
- Neutralizing antibody evasion of SARS-CoV-2 JN.1 derivatives KP.3, KP.3.1.1, LB.1, and XEC
Kaori Sano, Kei Miyakawa, … Hideki Hasegawa·VaccinePeer-reviewed·Nov 5, 2024
- Preclinical Characterization of the Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine
K. Modjarrad, Y. Che, … K. Swanson·bioRxiv·Nov 17, 2023